Chimeric Therapeutics Future Growth
Future criteria checks 0/6
Chimeric Therapeutics's revenue and earnings are forecast to decline at 171.6% and 42.3% per annum respectively while EPS is expected to grow by 171.6% per annum.
Key information
-42.3%
Earnings growth rate
171.6%
EPS growth rate
| Biotechs earnings growth | 16.1% |
| Revenue growth rate | -171.6% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 08 Apr 2024 |
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2025 | N/A | -21 | N/A | -17 | 1 |
| 6/30/2024 | N/A | -13 | N/A | -10 | 1 |
| 12/31/2023 | 12 | -12 | -8 | -8 | N/A |
| 9/30/2023 | 8 | -19 | -12 | -12 | N/A |
| 6/30/2023 | 5 | -26 | -16 | -16 | N/A |
| 3/31/2023 | 5 | -22 | -18 | -18 | N/A |
| 12/31/2022 | 6 | -18 | -20 | -20 | N/A |
| 9/30/2022 | 4 | -17 | -17 | -16 | N/A |
| 6/30/2022 | 3 | -16 | -14 | -13 | N/A |
| 3/31/2022 | 1 | -19 | -15 | -13 | N/A |
| 12/31/2021 | N/A | -21 | -16 | -13 | N/A |
| 9/30/2021 | N/A | -18 | -15 | -11 | N/A |
| 6/30/2021 | N/A | -15 | -14 | -9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CHM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CHM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CHM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CHM is forecast to have no revenue next year.
High Growth Revenue: CHM is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CHM's Return on Equity is forecast to be high in 3 years time